Company Overview and News


Add SRPT
to your dashboard

Headline News

Biotech Forum Daily Digest: What Now For Sarepta?

2017-11-21 seekingalpha
Biotech fell to begin the holiday shortened trading week, continuing a bout of poor performance in the fourth quarter of this year. (143-1)

An Upcoming Conversation With An Expert: The U.S. Launch Of Exondys 51 For DMD

2017-11-21 seekingalpha
We’re interviewing a physician treating DMD patients who has prescribed the drug in the US outside of clinical trials. (19-1)

Ultragenyx's MEPSEVII: A Look At The MPS Drug's Commercial Potential

2017-11-21 seekingalpha
Much of the upside will come from pricing but better diagnosis of MPS patients could boost sales. (26-1)

Ultragenyx Reaches The Finish Line For Rare Disease

2017-11-21 seekingalpha
Ultragenyx receives FDA approval to treat a rare disease with its drug MEPSEVII, which sets it up to generate revenue. (94-1)

Six promising stocks to buy when the biotech correction ends - MarketWatch

2017-11-20 marketwatch
Some investors are waiting for a decline in the U.S. stock market to put new money to work. (105-1)

Spark Therapeutics: Buy The Dip

2017-11-20 seekingalpha
I've written a couple pieces on this gene therapy pioneer in the past with mixed success. (22-1)

Taking A Post Approval Look At Ultragenyx

2017-11-16 seekingalpha
Shares have risen just 12% over the past three years and slid over 30% year to date. (22-0)

Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?

2017-11-15 zacks
Investors in Sarepta Therapeutics, Inc. (SRPT - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17th 2017 $33.00 Put had some of the highest implied volatility of all equity options today. (20-0)

Biotech ETFs: What Lies Ahead?

2017-11-13 zacks
So far, it’s been a good year for biotech stocks with the Nasdaq Biotechnology Index soaring 19.6% year to date. This is in sharp contrast to last year’s performance when the Index was down 19.1% with several factors including the drug pricing controversy weighing on the sector. (177-0)

S&P 500 Weekly Update: The Bull Market Rolls On Setting Records Along The Way.

2017-11-10 seekingalpha
More all time highs for the Dow, Nasdaq and the S&P this week. The dominant trend remains higher. (20-0)

Sarepta Therapeutics - Insider Buying And What The Capital Raise Means

2017-11-09 seekingalpha
CEO Doug Ingram is buying into the long term prospects of the company with his own money. (19-0)

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment - Channel NewsAsia

2017-11-09 channelnewsasia
Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary." (146-0)

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

2017-11-09 reuters
NEW YORK (Reuters) - Health insurer Anthem Inc has eased access to Sarepta Therapeutics’ treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to “medically necessary.” (146-0)

IFR Americas ECM Pipeline

2017-11-09 reuters
Nov 8, 2017 - PRICED: Apellis Pharmaceuticals (US, biotech) – $150m IPO. 10.71m shares (100% prim) at$14 versus marketing at $13-$15. CITI, JPM. Cadence Bancorp (US, commercial bank) – $209m FO. 9.5m shares (100% sec) at $22.00 versus $23.00 last sale and $25.46 launch. GS, JPM. Sogou (Cayman Islands/China, internet search) – $585m IPO. 45m ADSs (100% prim) at $13.00 versus marketing at $11-$13. JPM, CS, GS, CICC, CREN. (33-0)

Sarepta Therapeutics Will Continue To Ride High On EXONDYS 51's Success In 2017

2017-11-08 seekingalpha
EXONDYS 51 is seeing rising demand, thanks to increasing adoption of genetic testing and higher patient compliance rates. (210-1)

CUSIP: 803607100